On May 16, the U.S. Food and Drug Administration approved LUCEMYRA™ (lofexidine hydrochloride), a non-opioid medication for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. LUCEMYRA is marketed by US WorldMeds and expected to be commercially available in the United States in August 2018. LUCEMYRA is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing physical dependence and OUD. In clinical trials, people who received LUCEMYRA experienced improvement of withdrawal symptoms and completed the preplanned treatment period more frequently . . .